There are still some kinks to be ironed out, including risks of hemolysis and valve thrombosis, to put things on par with ...

Erlanger Health announces the recent completion of surgeries using new Pulsed Field Ablation (PFA) technology to better treat patients battling atrial fibrillation (AFib). Officials said, "As the ...

EMPAVELI's key market opportunities include its strong differentiation through C3 inhibition, capturing PNH patients inadequately controlled by C5 inhibitors. Expansion into rare kidney diseases, ...

Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of ...

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the submission of ...

Detailed results from RISE UP Phase 3 trial of mitapivat in sickle cell disease selected for distinguished Plenary Abstracts Session; Company to host investor conference call and ...

Agios Pharmaceuticals has submitted a supplemental New Drug Application to the FDA seeking accelerated approval of mitapivat for sickle cell disease, supported by Phase 2/3 RISE UP data showing ...

Glomerular hyperfiltration was observed in 82.6% of 46 pediatric patients with sickle cell disease, while an elevated urinary protein-creatinine ratio affected 32.6%.

A 26‑year‑old man with sickle cell disease (SCD) developed life‑threatening hyperhemolysis that progressed despite transfusion and high‑dose steroids, requiring intensive care and mechanical ...

Document suggests federal health agency pointed out some of the same concerns repeatedly since 2022 without resolution ...

This study represents the first report of loading TIG onto hemoglobin (HB) nanoparticles. This system utilizes the iron ...